awmsg logo



alteplase (Actilyse® Cathflo®)


Reference No. 722

Publication date:
12/01/2012


Appraisal information

alteplase (Actilyse® Cathflo®) 2 mg powder and solvent for solution for injection/infusion


Company: Boehringer Ingelheim Ltd
BNF category: Cardiovascular system
NMG meeting date: 03/11/2011
AWMSG meeting date: 07/12/2011
   
   
Submission Type: Limited Submission
Status: Recommended
Advice No: 1911
Ministerial ratification: 09/01/2012

Current Progress


Submission
received
NMG
meeting
AWMSG
meeting
Ministerial
Ratification

AWMSG advice

Alteplase (Actilyse® Cathflo® 2 mg) is recommended as an option for use within NHS Wales for the thrombolytic treatment of occluded central venous access devices including those used for haemodialysis. AWMSG is of the opinion that alteplase (Actilyse® Cathflo® 2 mg) is not suitable for shared care within NHS Wales.
Final Appraisal Recommendation (FAR)
Download
AWMSG Secretariat Appraisal Report (ASAR)
Download